Key Takeaways
- Stable quarter, cautious tone: Revenue grew 3.6% QoQ with EBITDA held at 16.1%, but management declined to give FY27 growth guidance, citing macro volatility and AI-led changes that make book-and-ship uncertain.
- Financial Services is the clear growth engine: The vertical improved sharply on the back of two large North American FS wins plus U.K. and AMEA institutions, with revenue and resources now ramping.
- North America reset is showing green shoots: After a year of leadership and GTM reset, the region posted its second straight quarter of positive sequential order book growth, though revenue remains flat as older projects roll off.
- AI deals are building but still small: Over 27 net new AI programs were added in Q4, but the average deal size is ~$1 million and management cannot say when enterprise-scale AI revenue will materialize.
- What to watch next quarter: Whether North America order book growth converts to revenue, the pace of Healthcare recovery from its timing gap, and any stabilization in AMEA if geopolitical headwinds ease.
Demand Environment & Revenue Performance
- Q4 revenue drivers: Financial Services was the star, with improvement driven by order book closed earlier with two large North American FS institutions plus others in the U.K. and AMEA; revenue and resources are ramping. Retail and Manufacturing were stable with a timing dip of around 2%.
- Healthcare dip is a timing gap, not demand loss: In both the U.K. and North America, current projects went live or ramped down while newer programs are yet to be contracted or started. Growth is expected to return soon.
- Public Sector stability: Several contracts were renewed, providing good long-term visibility.
- U.K. & Europe delivered for the full year: The region grew 11% in pound terms and 21.8% in INR terms for FY26, with healthcare as the dominant growth factor. U.K. Healthcare specifically grew 24% in dollar terms and 90+% in INR terms, focused on the NHS as a key customer.
- North America revenue still flat: The year was a fundamental reset of leadership, teams, target markets and GTMs. Most of that is now stabilized, but revenue was largely flat in Q4 due to right-shifting of some projects. The business is more project-based, so older projects ramp down while the order book ramps up.
- AMEA faces geopolitical drag: The Middle East is seeing short-term headwinds from geopolitical turbulence. WAR revenue of ~$0.5 million recognized in Q4 helped keep the business stable. Excluding geopolitical uncertainties, AMEA is turning around towards growth in FY27.
- Order backlog provides a stronger FY27 foundation: The 12-month order backlog is stronger entering FY27 than it was entering FY26. However, the market is more volatile with macro and AI-led changes, and book-and-ship within the year faces uncertainties. FY27 should be a positive growth year, faster than FY26, but management urges caution.
- Active client churn is planned rationalization: The active client count has dipped since FY24 due to deliberate rationalization of tail accounts. The top 50 to 100 customers are stable and growing; smaller customers and some project-based clients churn out consistently once a transformation project is completed.
Umang Nahata: "We believe it will be a growth year next year based on the fundamentals that have improved in this fiscal."
AI Strategy & Deal Evolution
- Two categories of AI deals: AI-led technology deals use 70 to 80% AI for execution and are moderately large; AI use-case deployments are early-stage discovery programs with small deal sizes but phenomenal value and impact. Margins on both are within the same range as current gross margin percentages.
- AI programs are accumulating: More than 27 net new AI-focused customer projects or programs were added in Q4, including both AI-for-tech and AI-for-business programs, with some significant AI roadmap engagements.
- The thesis on services demand: While AI reduces effort for writing code, it creates new opportunities: clients must relook at business processes, workflows, decision-making and create new revenue opportunities. Services will shift from developing to helping clients with workflow redesign, technology adoption and delivering outcomes.
- Platform ROI is not yet visible to clients: Many non-IT clients have bought AI platform licenses but the ROI is not yet visible. Significant surrounding services are needed for readiness, business process change, ROI adoption frameworks and governance. These are still in smaller discovery stages; enterprise scale will significantly increase revenue but exact timing is unknown.
- Oracle business is pivoting to AI transformation: Core tech areas like coding, testing and managed services have become far more advanced, reducing human effort. However, client investment in platform modernization, AI workflows, infrastructure and capital allocation for AI is significant and far outruns employee-related cost savings. Oracle transformation projects are becoming AI transformation projects, putting Mastek in a position to deliver AI adoption in back-office areas and then propose for front-office work.
- Scalability question is unanswered: The average AI deal size is small, and management described a general build-up path from AI-for-tech to AI-for-business but did not provide a specific scalability path or timeline for when enterprise-scale revenue will materialize.
Umang Nahata: "When it becomes enterprise scale, and it will become enterprise scale because it is not just about 1 or 2 workflows. It has to change the entire landscape of business. That's where sizable revenue and business impact will happen, which will clearly overthrow whatever we have been doing so far and significantly increase that. But like I said, I can only tell you lead indicators, exact timing is unknown."
Margins & Efficiency
- Q4 margin walk: EBITDA was maintained at 16.1%. A salary increase impact of $1.1 million (1.1% on EBITDA) was offset by a forex tailwind of 0.8% and execution of cost efficiencies.
- Full-year margin resilience: Full-year EBITDA of 15.8% was the same as the previous year despite pricing pressures and macroeconomic situations, reflecting what management calls the resiliency of its AI-led operating model.
- U.S. and Middle East margins down: North America margins fell YoY and sequentially due to revenue still stabilizing and the wage hike impact. AMEA margins also declined as revenue did not move significantly while the wage hike hit.
- Revenue per resource improved: The metric rose more than 12% in the year, delivering efficiency gains to clients. Headcount has been consistently reduced, especially in the fixed-bid business, due to the ability to do more with fewer employees. Employee growth rate will be slower than revenue growth going forward.
- FY27 margin commitment is flat: Management expects to maintain margin at 16% to 16.1%, balancing operational efficiency, AI-led efficiency, price competitiveness, client budget reduction asks and new AI investments.
- Business model is shifting from T&M to outcome-based: Renewals are extremely price competitive across the board, with discounts that can go much higher than 10% to 15%, driven by AI enabling faster and better delivery with less effort. The company is shifting from T&M to more fixed-bid, outcome-based contracts. Fixed-bid percentages, currently around 40% company-wide and over 50 to 55% in North America, will grow further.
Umang Nahata: "The T&M model will give way to more outcome-focused model."
Geographic & Vertical Reset
- North America turnaround is in early motion: FY26 was a fundamental reset. Q4 was the second quarter of positive sequential order book growth, and lead indicators point to continued sequential growth in coming quarters. FY27 is expected to be a good growth year for North America.
- AMEA is refocusing on core verticals: The business has reset its focus on healthcare, BFSI and manufacturing, shifting from back-office work to bedside, clinical and patient engagement activities, especially on Oracle Health. Geopolitical uncertainties are the main wildcard; excluding those, AMEA is turning around towards growth in FY27.
- U.K. Healthcare is a standout: The vertical grew 24% in dollar terms and 90+% in INR terms for FY26, focused on the NHS as a key customer.
- FCA deal is ramping: The deal announced in March has already started with more than 60 on-site resources on the account and is expected to be fully ramped up by the end of Q1. The ATLAS and Biometric deals, existing renewals with expanded scope, are in SOW negotiation with ramp-ups expected between Q1 and Q2.
Capital Allocation & Corporate Actions
- Labor Code impact fully recognized: An exceptional and incremental impact of INR23.7 crores was recognized in Q4 (gratuity INR16 crores, leave encashment INR7.7 crores), in addition to INR6.4 crores in Q3. This was classified as an exceptional item below EBITDA after clarification from the Labor Ministry and an independent external review. Q3 EBITDA was reinstated from 16.1% to 16.8%.
- Entity merger completed: Mastek Enterprise Solutions Private Limited, a wholly owned subsidiary, was merged into Mastek Limited to simplify the entity structure in India and eliminate duplicate costs. The FY25 balance sheet was restated.
- Dividend declared: A final dividend of INR16 per share was declared, on top of an INR8 interim dividend, totaling 480% of face value.
- M&A thesis is tightening: M&A focus is now on expanding domain capabilities in core focus areas, not just technology skills. The company is also looking at strategic but smaller AI investments and partnerships with significant AI players.
- Tax rate steady: The average effective tax rate going forward is 24.5% to 24.7%, expected to continue in future quarters.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | FY27 will be a positive growth year, faster than FY26, based on improved fundamentals and order backlog | FY27 |
| EBITDA margin | Maintain at 16% to 16.1%, balancing efficiency gains against pricing pressure and AI investments | FY27 |
| North America turnaround | Order book growth to continue sequentially, resulting in positive revenue growth | FY27 |
| Healthcare recovery | Growth expected to return soon; timing gap between projects going live and new ones starting | Near term, undated |
| FCA deal ramp-up | Fully ramped up with resources deployed | End of Q1 FY27 |
| ATLAS & Biometric ramp-ups | New SOWs being negotiated; ramp-ups expected | Between Q1 and Q2 FY27 |
| AMEA turnaround | Turning towards growth, conditional on geopolitical uncertainties being eliminated | FY27, conditional |
| Tax rate | Average effective rate of 24.5% to 24.7% | Ongoing |
| Business model shift | Fixed-bid percentages to grow further from ~40% company-wide and >50-55% in North America | Undated |
| Headcount efficiency | Employee growth rate will be slower than revenue growth; revenue per resource to move positively | Undated |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | $103.5 million, +1.4% QoQ; +0.3% QoQ in constant currency |
| Revenue (INR) | ₹938 crores, +3.6% QoQ and +3.6% YoY |
| Operating EBITDA margin | 16.1%, salary increase impact of 1.1% offset by forex tailwind of 0.8% and cost efficiencies |
| PAT | ₹106 crores, 11% of revenue; -0.7% QoQ due to Labor Code true-up impact |
| 12-month order backlog | $300.4 million, +1.5% QoQ and +13.5% YoY in USD; +24.4% YoY in INR |
| Order backlog growth (INR) | +7.2% QoQ; +1.6% QoQ in USD terms |
| Full-year FY26 revenue | $421.2 million, +3.1% YoY; ₹3,699 crores, +7% YoY |
| Full-year FY26 EBITDA margin | 15.8%, flat YoY |
| Full-year FY26 PAT | ₹404 crores, +7.5% YoY; 10.7% of total income, flat YoY |
| Basic EPS (FY26) | ₹130.45, +7.1% YoY |
| Diluted EPS (FY26) | ₹129.5, +7.3% YoY |
| Operating cash flow (FY26) | ₹542 crores, +35% YoY |
| Cash and cash equivalents | ₹938 crores as of March 2026, +51% YoY |
| DSO | 73 days, lowest in last 12 quarters; Q4 collections of $125 million |
| Total headcount | 4,730, net addition of 54 during the quarter |
| Utilization rate | 80%, +3.3 ppt QoQ and +1.7 ppt from Q2 |
| Revenue per resource growth (FY26) | +12% for the full year |
| New customers added | 12 during the quarter |
| Net new AI-focused customer programs | 27 programs added in the quarter |
| U.K. & Europe revenue growth (FY26) | ~11% in pound terms; 21.8% in INR terms |
| U.K. healthcare revenue growth (FY26) | ~24% in dollar terms; 90-plus percent in INR terms |
| U.K. EBITDA margin | ~20% |
| Fixed-bid business share | ~40% at company level; >50–55% in North America |
| Labor Code exceptional impact (Q4) | ₹23.7 crores incremental impact, including gratuity of ₹16 crores and leave encashment of ₹7.7 crores |
| Dividend | ₹16 per share final dividend, on top of ₹8 interim; total 480% of face value |